Delving into the Latest Updates on Diatrizoate Sodium/Meglumin diatrizoate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Gastroview, Gastrografin

Target-

Mechanism-

Therapeutic Areas

Other Diseases

Active Indication

Contrast agents

Inactive Indication-

Originator Organization

G&E Healthcare Co., Ltd.

Active Organization

G&E Healthcare Co., Ltd.Bracco Diagnostics, Inc.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

US (02 Aug 1955),

Contrast agents

Regulation-

Login to view timeline

Structure

Molecular FormulaC18H26I3N3O9

InChIKeyMIKKOBKEXMRYFQ-WZTVWXICSA-N

CAS Registry131-49-7

View All Structures (2)

Small bowel obstruction (SBO) is one of the most common causes of serious gastrointestinal disease in the US. Adhesion-related SBO (aSBO) is usually treated by the placement of a nasogastric tube (NGT) to decompress the stomach, administration of intravenous (IV) fluids and observation by a surgical team.
The purpose of this feasibility study is to determine the potential for implementation of treatment protocols for aSBO and determine the feasibility of randomizing patients with aSBO to receive or not receive NGTs or water-soluble contrast (WSC). The investigators will also determine the ability to measure HRQOL as a main outcome for the treatment of aSBO. The studies outlined in this research program intend to address gaps in knowledge about how to determine who benefits from NGT placement, who can be managed without them, how to objectively determine when a bowel obstruction has resolved, how to reintroduce feeding to patients with aSBO, what criteria should be used for hospital discharge and what role cathartics such as WSC contrast have in the management of aSBO.
This feasibility study will enroll a limited number of patients (n=40) who will be followed for up to 30 days.

Start Date01 Jan 2024

Sponsor / Collaborator

University of California, Los Angeles

NCT05726097 / CompletedPhase 3

Optimization of the Bowel Preparation Regimen for Colon Capsule Endoscopy Procedure

The study aims to investigate the effect of the optimized bowel preparation and boost regimens on colon capsule endoscopy procedures, specifically on cleanliness and completion rate.

Start Date01 Feb 2023

Sponsor / Collaborator

Region Skåne Holding AB

[+2]

ACTRN12620000710921 / RecruitingNot ApplicableIIT

A Phase 2 study of efficacy: The validation of Gastrografin measurement in postsurgical samples following low anterior resection when the rectal tube is flushed with Gastrografin

Start Date18 Aug 2020

Sponsor / Collaborator-

100 Clinical Results associated with Diatrizoate Sodium/Meglumin diatrizoate

Login to view more data

100 Translational Medicine associated with Diatrizoate Sodium/Meglumin diatrizoate

Login to view more data

100 Patents (Medical) associated with Diatrizoate Sodium/Meglumin diatrizoate

Login to view more data

431

Literatures (Medical) associated with Diatrizoate Sodium/Meglumin diatrizoate

01 Jan 2025·Radiology Case Reports

Complicated meconium ileus in a male neonate with cystic fibrosis: Case report

Article

Author: Abilkassem, Rachid ; Agadr, Aomar ; Sellouti, Mohamed

In about 10%-15% of instances, meconium ileus (MI) is the first sign of cystic fibrosis (CF). If a newborn exhibits signs of intestinal obstruction and does not pass meconium within a short period of time after birth, MI is suspected. The cystic fibrosis transmembrane conductance regulator gene (CFTR), which is found on chromosome 7q31, is mutated in CF patients. A premature baby, 5 days old, with clinical signs that were typical of MI. These attempts failed in spite of conservative therapies, such as rectal injection of gastrografin. An ileostomy was made and meconium was manually evacuated after an exploratory laparotomy revealed the presence of a typical MI. At ≥1300 µg/L (reference value ≤1000 µg/L), immunoreactive trypsinogen (IRT) levels were increased, which prompted the start of oral pancreatic enzyme replacement treatment. Discharge at 65 days of age included referrals to primary care and a specialized CF clinic. The baby has since shown normal growth and development. This case highlights the rapid onset of CF in a premature infant with complex MI as the initial clinical presentation.

09 Nov 2024·Cureus

Streamlining the Non-operative Management of Adhesive Small Bowel Obstruction: A Closed-Loop Audit Evaluating the Introduction of a Standardised Gastrografin Protocol in a District General Hospital

Article

Author: Rehman, Saif ; Baho, Yousif ; Farinella, Eriberto ; Thakur, Apoorva

Introduction Adhesive small bowel obstruction (ASBO) is a common cause of admissions to general surgery services. Water-soluble contrast (WSC), such as Gastrografin® (GGF), can be utilised in the conservative management of patients with ASBO, with predictive and possible therapeutic value. We audited the non-operative management of ASBO in the general surgery department of East and North Hertfordshire NHS Trust, a district general hospital. Following the introduction of a hospital-wide protocol standardising the use of GGF in patients with ASBO, a re-audit was conducted to assess its impact. Methods A retrospective audit of ASBO patients who received GGF was conducted in two cycles: before and after the implementation of the protocol. Data were collected between February and June 2022 for group 1 (pre-protocol) and between August and November 2023 for group 2 (post-protocol). Results Forty-eight patients were included in the analysis across both groups: 31 in group 1 (pre-protocol) and 17 in group 2 (post-protocol). The success rate of this non-operative trial with GGF increased from 77% (24/31) in group 1 to 88% (15/17) in group 2. The median duration of conservative management was two days in both groups. The median time from CT scan to GGF administration decreased from 24 hours in group 1 to 19 hours 22 minutes in group 2, and the interval between GGF administration and first abdominal radiograph decreased from 9 hours in group 1 to 6 hours 25 minutes in group 2. Conclusion Our closed-loop audit suggests that by streamlining the non-operative management pathway of adhesive small bowel obstruction, our standardised protocol is safe and possibly improves efficiency within a district general hospital setting.

01 May 2024·Journal of Trauma and Acute Care Surgery

Improving outcomes in emergency general surgery: Construct of a collaborative quality initiative

Article

Author: Yang, Amanda Y ; Mikhail, Judy N ; Gerhardinger, Laura ; Kramer, Kim A ; Scott, John W ; Golden, Roy J ; Hemmila, Mark R ; Hoppe, Beckie L ; Mitchell, Eric J ; Napolitano, Lena M ; Neiman, Pooja U ; Lindsey, Hugh J ; Jakubus, Jill L

BACKGROUNDEmergency general surgery conditions are common, costly, and highly morbid. The proportion of excess morbidity due to variation in health systems and processes of care is poorly understood. We constructed a collaborative quality initiative for emergency general surgery to investigate the emergency general surgery care provided and guide process improvements.METHODSWe collected data at 10 hospitals from July 2019 to December 2022. Five cohorts were defined: acute appendicitis, acute gallbladder disease, small bowel obstruction, emergency laparotomy, and overall aggregate. Processes and inpatient outcomes investigated included operative versus nonoperative management, mortality, morbidity (mortality and/or complication), readmissions, and length of stay. Multivariable risk adjustment accounted for variations in demographic, comorbid, anatomic, and disease traits.RESULTSOf the 19,956 emergency general surgery patients, 56.8% were female and 82.8% were White, and the mean (SD) age was 53.3 (20.8) years. After accounting for patient and disease factors, the adjusted aggregate mortality rate was 3.5% (95% confidence interval [CI], 3.2–3.7), morbidity rate was 27.6% (95% CI, 27.0–28.3), and the readmission rate was 15.1% (95% CI, 14.6–15.6). Operative management varied between hospitals from 70.9% to 96.9% for acute appendicitis and 19.8% to 79.4% for small bowel obstruction. Significant differences in outcomes between hospitals were observed with high- and low-outlier performers identified after risk adjustment in the overall cohort for mortality, morbidity, and readmissions. The use of a Gastrografin challenge in patients with a small bowel obstruction ranged from 10.7% to 61.4% of patients. In patients who underwent initial nonoperative management of acute cholecystitis, 51.5% had a cholecystostomy tube placed. The cholecystostomy tube placement rate ranged from 23.5% to 62.1% across hospitals.CONCLUSIONA multihospital emergency general surgery collaborative reveals high morbidity with substantial variability in processes and outcomes among hospitals. A targeted collaborative quality improvement effort can identify outliers in emergency general surgery care and may provide a mechanism to optimize outcomes.LEVEL OF EVIDENCETherapeutic/Care Management; Level III.

100 Deals associated with Diatrizoate Sodium/Meglumin diatrizoate

Login to view more data

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Contrast agents	US	Bracco Diagnostics, Inc.	02 Aug 1955

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01440712 (Pubmed \| World J Surg)	Phase 4	Postoperative ileus	-	Gastrografin	ghurutsnhm(xnpxsbnrvf) = vgprgtnnhs mfjajjhzpo (pnxzzguywu, 6.51 - 11.68)	Negative	01 Jan 2016
				Placebo	ghurutsnhm(xnpxsbnrvf) = xtaizuqzhm mfjajjhzpo (pnxzzguywu, 6.96 - 10.29)
UEGW	Not Applicable	Intrauterine Growth Retardation, Metaphyseal Dysplasia, Adrenal Hypoplasia Congenita, and Genital Anomalies	-	Prep2 (2L PEG + Ascorbate + low dose NaP + gastrografin)	zrahsjizcg(qyjhzoebkk) = yahhooynbk ihfbbsfpmf (pwunjvbhcv ) View more	-	01 Oct 2015
NCT01515696 (CTgov)	Phase 4	Meconium Ileus	96	Gastrografin (Gastrografin)	hibycgazlq(ekrcldxkhv) = dkmrqqsybc xdjzddtrvn (agavwunvmo, vooqopetvc - qiyhhkyyma) View more	-	18 Jul 2014
				sterile water (Sterile Water)	hibycgazlq(ekrcldxkhv) = hwopcaqwoq xdjzddtrvn (agavwunvmo, vemeqssavu - ygawzdlxrd) View more